Guest guest Posted January 11, 2011 Report Share Posted January 11, 2011 Dear Members,Ximelagatran was the first oral direct thrombin inhibitor approved; however, it was subsequently withdrawn from the market because concerns of hepatic toxicity. Recently a new oral direct thrombin inhibitor, dabigatran, was approved for use in Europe for prevention of venous thromboembolism in patients who have undergone hip or knee replacement surgery. This drug has been shown to have equivalent efficacy and safety to LMWH. No routine monitoring is required. Thus, this drug has significant advantages over warfarin, which has a narrow therapeutic window, is affected by diet and many drugs, and requires monitoring for dosage adjustment. It appears that the direct thrombin inhibitors are poised to challenge warfarin's dominance in the prevention and therapy of thrombotic disease. Regards,Dr. Vijaya Chaudhari.JR-3,Dept. of Pharmacology,Government Medical College, Nagpur. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.